BIO-CEO Wraps Up 19th Annual Investor Conference

Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on […]

Read more »

Cellular Biomedicine Group Joins Force With Huntsworth Health For KOL Advocacy On Clinical Research For Knee Osteoarthritis

Cellular Biomedicine Group, Inc. (CBMG) has took on Hunstworth Health to put in order a team of medical experts for […]

Read more »

Aeolus Pharma’s AEOL 10150 Declared Orphan Drug for IPF and Lung-ARS

The US FDA recently announced that the experimental drug being developed by Aeolus Pharmaceuticals, Inc. AEOL 10150 has been granted […]

Read more »

SpectraScience: Innovations in Cancer Detection

SpectraScience has developed patented platform technology that diagnoses colorectal cancer, which has a market size of $1, 442.6 million.

Read more »

DesignMedix: Overcoming Drug Resistance

DesignMedix places great emphasis on tackling problems of drug resistant diseases, such as malaria, bacteria, and cancer.

Read more »

Avantis Medical Systems Enters Enormous Endoscope Market

Avantis Medical Systems is company that is tapping into large Endoscope market which has 30 million colonoscopies globally and 15 million in the US alone.

Read more »

Monteris Medical Develops a Novel Treatment for Glioblastoma

Monteris Medical is a neurosurgical company with a focus on creating unique and innovative technology to treat serious brain disorders. Their flagship product, the Neuroblate Thermal Therapy System creates minimally invasive treatments for soft tissue and brain lesions

Read more »

Diagnovus Focused on Delivering Personalized Diagnostic Information and Services to Physicians Treating Patients Suffering from Rare Diseases

Diagnovus is a specialized molecular diagnostic company, focused on delivering personalized diagnostic information and services to physicians treating patients suffering from rare, orphan and less frequent diseases. We are privileged for the opportunity to serve patients and the physicians treating them.

Read more »

Profound Medical’s Device on Fast Track for Commercialization

Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.

Read more »

OneMedForum Recap: Del Mar Pharmaceuticals

Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications specifically where patients have failed contemporary therapy.

Read more »